Responses
Clinical/translational cancer immunotherapy
Original research
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
